Clinical trials: Acute Leukemia, open to volunteers
Acute Myeloid Leukemia (AML), MLL Rearrangement
Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement.
- Trial name
- MLL-LSC (NCT07537738)
- Testing
- Detection of leukemia stem cell using multiparameter flow cytometry
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Peking University People's Hospital
B Cell Lymphoma, Acute Lymphoblastic Leukemia
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
1. Study Title: A Study on the Efficacy and safety of Autocrine p40-Expressing CD19-Targeted Chimeric Antigen Receptor T Cells (CD19-CAR.p40-T) in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies 2.
- Conditions
- B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- CAR-p40-T (NCT07584889)
- Testing
- CAR-T cell
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen University General Hospital
CD7+ Lymphoma, CD7+ Acute Leukemia
CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia
CD7 molecules are thought to be associated with disease aggressiveness, drug resistance, and poor prognosis. Intensive chemotherapy, immunotherapy, hematopoietic stem cell transplantation (HSCT) and other treatment regimens have…
- Trial name
- NCT07008872
- Testing
- CD7 CART
- Volunteers
- 40 people
- Sponsor
- Qi deng
Leukemia Acute Myeloid
Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML
This study is testing a new treatment combination called RAVEN, which includes revumenib, azacitidine, and venetoclax, in patients who are newly diagnosed with a specific type of acute myeloid leukemia (AML) called KMT2A…
- Trial name
- RAVEN (NCT07605949)
- Testing
- Azacitidine, Venetoclax, Revumenib
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Childhood Acute Lymphoblastic Leukemia
NUDT15/TPMT Multi-gene Guided 6-MP Dosing in Childhood ALL Maintenance Therapy
This is a prospective, single-center clinical study to evaluate the safety and efficacy of a personalized 6-mercaptopurine (6-MP) dosing strategy guided by NUDT15 and TPMT genotypes in children with Acute Lymphoblastic Leukemia…
- Trial name
- NCT07462299
- Testing
- NUDT15/TPMT genotype-guided 6-MP dosing
- Where
- China
- Volunteers
- 110 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
- Trial name
- HEM-iSMART E (NCT07175415)
- Testing
- Capivasertib, Venetoclax, Dexamethasone
- Volunteers
- 42 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of improvement (recurrent) or that…
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT07012044
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 15 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
This phase I trial identifies the best dose and clinical benefit of giving pemigatinib following standard induction chemotherapy in patients with newly diagnosed acute myeloid leukemia.
- Trial name
- NCT04659616
- Testing
- Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- OHSU Knight Cancer Institute
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML).
- Trial name
- NCT07022678
- Testing
- Best Practice, Biospecimen Collection, Cytarabine
- Where
- 39 sites in United States
- Volunteers
- 556 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukaemia (AML)
Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML
To evaluate the 12-month relapse free survival with weekly Decitabine/cedazuridine plus Venetoclax in AML maintenance after achieving composite CR (CR, CRi, CRh)
- Trial name
- NCT07867626
- Testing
- Venetoclax, Decitabine/Cedaruridine, decitabine/cedazuridine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Rutgers, The State University of New Jersey
Acute Lymphoblastic Leukemia
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
Researchers are looking for new ways to treat people with a type of blood cancer called precursor B-cell Acute Lymphoblastic Leukemia (B-ALL) that is relapsed- the cancer has come back after treatment, or refractory - the current…
- Trial name
- NCT05579132
- Testing
- MK-1045
- Where
- 11 sites in China
- Volunteers
- 203 people
- Sponsor
- MSD R&D (China) Co., Ltd.
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of S241656 and to determine the recommended dose for expansion (RDE) of S241656 in participants with relapsed/refractory (R/R) acute…
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Acute Myeloid Leukemia
- Trial name
- NCT07719348
- Testing
- S241656, Posaconazole
- Volunteers
- 64 people
- Sponsor
- Servier
AML, MDS
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide…
- Conditions
- AML, MDS, Acute Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07493538
- Testing
- Treosulfan, Fludarabine, Total Body Irradiation
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Breast Cancer Female, Acute Leukemia
Use of GnRHa During Chemotherapy for Fertility Protection
Many cytotoxic drugs may harm the fertility of young women treated for cancer. The aim of the study is to investigate if the Gonadotropin-Releasing Hormone agonist (GnRHa) during cancer treatment can preserve the fertility of…
- Conditions
- Breast Cancer Female, Acute Leukemia, Lymphoma, Osteosarcoma
- Trial name
- ProFertil (NCT05328258)
- Testing
- Triptorelin Embonate, Sodium Chloride solution 0.9%
- Where
- 17 sites in Sweden
- Volunteers
- 500 people
- Sponsor
- Kenny Rodriguez-Wallberg
Leukemia, Myeloid, Leukemia
Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
This study is to evaluate the safety and preliminary efficacy of adding the PI3K-gamma inhibitor, eganelisib, to a standard of care treatment option with combination venetoclax and azacitidine in participants with acute myeloid…
- Conditions
- Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia, Refractory Leukemia
- Trial name
- GAVEL (NCT07439211)
- Testing
- Eganelisib, Azacitidine, Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Jacqueline Garcia, MD
Acute Myeloid Leukemia
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
The standard treatment for patients with acute myeloid leukemia (AML) with an abnormality in the IDH1 gene, who are not eligible for intensive chemotherapy, is a combination of ivosidenib and azacitidine.
- Trial name
- EVOLVE 1 (NCT07075016)
- Testing
- Venetoclax 400
- Where
- 119 sites in Austria, Belgium and 14 more
- Volunteers
- 227 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Acute Myeloid Leukemia, Pediatric AML
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
This research study investigates the tolerability of substituting two cycles of chemotherapy into the standard pediatric acute myeloid leukemia (AML) chemotherapy treatment regimen for patients with newly diagnosed AML at…
- Trial name
- NCT07059975
- Testing
- Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Baylor College of Medicine
Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary
Venetoclax Basket Trial for High Risk Hematologic Malignancies
This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived…
- Conditions
- Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia
- Trial name
- NCT05292664
- Testing
- Venetoclax, Azacitidine, Cytarabine
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Andrew E. Place, MD
Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
This phase I trial studies the side effects and best dose of CD4+ and CD8+ HA-1 T cell receptor (TCR) (HA-1 T TCR) T cells in treating patients with acute leukemia that persists, has come back (recurrent) or does not respond to…
- Conditions
- Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT03326921
- Testing
- CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, B-Cell, Chronic, Leukemia
A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction
Combination of azacitidine (AZA) for 7 days every 28 days with a continuous daily exposure to Venetoclax (VEN), an oral bcl-2 inhibitor, is now approved for the treatment of acute myeloid leukemia (AML) in patients ineligible for…
- Trial name
- SEVENAZA (NCT07082452)
- Testing
- Venetoclax, Azacitidine
- Where
- France
- Volunteers
- 262 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.